KAIST 생명과학과동창회
  • News & Events
  • News

News

Antibiotic tolerance study paves way for new treatments


A new study identifies a mechanism that makes bacteria tolerant to penicillin and related antibiotics, findings that could lead to new therapies that boost the effectiveness of these treatments.


Antibiotic tolerance is the ability of bacteria to survive exposure to antibiotics, in contrast to antibiotic resistance, when bacteria actually grow in the presence of antibiotics. Tolerant bacteria can lead to infections that persist after treatment and may develop into resistance over time.

The study in mice, “A Multifaceted Cellular Damage Repair and Prevention Pathway Promotes High Level Tolerance to Beta-lactam Antibiotics,” published Feb. 3 in the journal EMBO Reports, reveals how tolerance occurs, thanks to a system that mitigates iron toxicity in bacteria that have been exposed to penicillin.


“We’re hoping we can design a drug or develop antibiotic adjuvants that would then basically kill off these tolerant cells,” said senior author Tobias Dörr, assistant professor of microbiology in the Weill Institute for Cell and Molecular Biology in the College of Agriculture and Life Sciences.


Co-authors included Ilana Brito, the Mong Family Sesquicentennial Faculty Scholar and assistant professor in the Meinig School of Biomedical Engineering in the College of Engineering, and Lars Westblade, associate professor of pathology and laboratory medicine at Weill Cornell Medicine.


Some bacteria, including the model bacterium used in the study, Vibrio cholerae, which causes cholera in humans, are remarkably tolerant to penicillin and related antibiotics, known as beta lactam antibiotics. It has been known for a long time that beta-lactam antibiotics break down bacterial cell walls, but how bacteria survive loss of their cell walls was poorly understood.


In the study, the researchers developed a V. cholerae mutant that lacked a two-component damage repair response system that controls a gene network encoding diverse functions. Without the system, known as VxrAB, when the cell wall is damaged by antibiotics, the transfer of electrons across the cell membrane goes awry, leading to electrons ending up on the wrong molecules. This misdirection causes hydrogen peroxide to accumulate in the cell, which changes the oxidation state of cellular iron and disrupts signals for the cell to tell how much iron it has.   


In the presence of hydrogen peroxide, the mutant bacteria cannot sense how much iron has been acquired, and it behaves as if it is iron-starved and seeks to acquire more iron. Left unchecked, these circumstances cause iron toxicity, which will kill the cell, according to the experiments the researchers conducted. In further tests with mutant V. cholerae bacteria, both in test tubes and in mice, the researchers showed that reducing the influx of iron increased the bacteria’s tolerance to beta lactams.


Fortunately for normal V. cholerae, exposure to antibiotics and the breakdown of the cell’s walls activate the VxrAB system, which works to repair cell walls and downregulates iron uptake systems, and thereby creates antibiotic tolerance. More study is needed to understand what triggers the VxrAB system in the presence of beta-lactam antibiotics.


The research opens the door for developing new drugs that could be combined with antibiotics to exploit oxidative damage and iron influx in tolerant bacteria. In future work, the researchers will search for parallel mechanisms of tolerance in other bacterial pathogens.


Jung-Ho Shin, a postdoctoral researcher in Dörr’s lab, is the paper’s first author. Co-authors include researchers from the Korea Advanced Institute of Science and Technology, the Korea Advanced Institute of Science and Technology, and the Intelligent Synthetic Biology Center in Korea.

The study was funded by the National Research Foundation of Korea and the National Institutes of Health.


https://news.cornell.edu/stories/2021/02/antibiotic-tolerance-study-paves-way-new-treatments

https://www.miragenews.com/antibiotic-tolerance-study-paves-way-for-new-516267/



List of Articles
번호 제목 글쓴이 날짜 조회 수
335 "당뇨병 합병증 치료단백질 개발!" - 고규영교수팀 과사무실 2006.03.14 13537
334 "어, 해독제가 항생제로 바뀌네" - 김학성 교수팀 단백질 설계기술 개발 과사무실 2006.02.07 13406
333 '마크로젠 과학자상'에 카이스트 김진우 교수 선정 생명과학과 2017.09.12 15522
332 1단계 BK21사업 성과보고대회 - 우수사업단 선정 및 부총리 표창 과사무실 2005.12.19 10950
331 2005학년도 석림학술장학재단 장학생 - 이영석 박사과정 학생 선정 과사무실 2005.12.29 11889
330 2007년 국가지정 연구실 선정.. 최길주 교수 연구실 과사무실 2007.07.20 12328
329 2008년 개교 37주년 기념 우수교원 포상 과사무실 2008.02.15 11169
328 2008년도 자연과학대학 우수 강의 교원 및 우수 직원 포상 과사무실 2008.04.29 11823
327 2009년 개교 38주년 기념 우수교원 포상 과사무실 2009.02.17 10996
326 2010년 개교 39주년 기념 우수교원 포상 과사무실 2010.02.11 11087
325 2011년 개교 40주년 기념 우수교원 포상 과사무실 2011.02.12 10592
324 2012년 개교 41주년 기념 우수교원 포상 과사무실 2012.02.11 10248
323 2014년 개교 43주년기념 우수교원 포상 과사무실 2014.02.14 10979
322 2015년 KAIST 대표 R&D 연구성과 10선 선정 / Announcement of KAIST's Top 10 Research Accomplishments of 2015 생명과학과 2016.03.07 10580
321 2020 Spring KAIST Compass 생명과학과 2020.05.07 2505
320 2020년 우수논문상 file 생명과학과 2020.04.03 3387
319 2단계 BK21 1차년도 연차평가결과 -생물분야 1위! 과사무실 2007.10.10 11758
318 2단계 BK21 <b>2년 연속 생물분야 1위!</b> 과사무실 2008.09.10 11018
317 BK21 생물사업단, 2단계 사업 1,2,3차년도 연차평가 생물분야 연속 1위! 과사무실 2009.12.29 10931
316 BK21사업 생물사업단 2단계 종합평가 결과 '매우우수', 교과부장관 표창! 과사무실 2012.09.07 11636
Board Pagination Prev 1 2 3 4 5 6 7 8 9 10 ... 17 Next
/ 17